Observing bone health in post-menopausal breast cancer patients after stopping certain treatments
Official title: Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors and Denosumab: An Observational Study to Assess Rebound Bone Loss and Insufficiency Fractures After Denosumab Discontinuation
Run by Memorial Sloan Kettering Cancer Center · NCT05590949 · Data updated 2026-11-12
This study looks at how stopping certain breast cancer treatments affects bone health in post-menopausal women over two years.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 100 (estimated) |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Drugs / interventions | denosumab |
| Locations | 7 sites (Basking Ridge, New Jersey and 6 other locations) |
| Status | Recruiting |
| Started | October 18, 2022 |
| Main results expected | October 18, 2027 |
| Study ends | October 18, 2027 |
| Registry record updated | November 4, 2026 |
| Trial ID | NCT05590949 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are post-menopausal women with a confirmed diagnosis of breast cancer who have stopped treatment with denosumab and aromatase inhibitors.
✕Probably not a fit
Patients with a history of osteoporosis or insufficiency fractures prior to starting denosumab may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect data on bone health changes in post-menopausal women with breast cancer who have discontinued treatment with denosumab and aromatase inhibitors. Participants will undergo health assessments, blood tests, and imaging over five clinic visits spanning 24 months. The study will help understand the impact of stopping these treatments on bone complications. By gathering this information, researchers hope to identify potential risks and inform future treatment strategies.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into bone health management for post-menopausal breast cancer patients after stopping specific therapies.
How similar studies have gone: While similar studies have explored bone health in breast cancer patients, this specific observational approach focusing on post-treatment changes is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women with Stage 0-3 breast cancer confirmed at MSKCC * Currently have no clinical evidence of disease * Participant must be post-menopausal, defined as last menstrual cycle at least 12 months prior to enrollment * Received at least 2 doses of denosumab and then discontinued therapy * Discontinued AI prior to or within 6 months of last denosumab injection * Patients must be 18 years of age or olde Exclusion Criteria: * Patients with history of osteoporosis prior to starting denosumab, based on previous dual-energy X-ray absorptiometry (DEXA) scan; * Patients with history of insufficiency fracture. * Patients who continue treatment with a different bone modifying agent (i.e oral or intravenous bisphosphonates) after discontinuation of denosumab * Patients on chronic low-dose glucosteroids.
Where it's running
-
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States Recruiting -
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, United States Recruiting -
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States Recruiting -
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities)
Commack, New York, United States Recruiting -
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, United States Recruiting -
Memorial Sloan Kettering Cancer Center
New York, New York, United States Recruiting
Show 1 more location
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, United States Recruiting
Study contacts
- Principal investigator: Monica Fornier, MD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Monica Fornier, MD
- Email: fornierm@mskcc.org
- Phone: 646-888-4563
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.